BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thompson RF, Mayekar SU, Zhai H, Both S, Apisarnthanarax S, Metz JM, Plastaras JP, Ben-Josef E. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41:081711. [PMID: 25086521 DOI: 10.1118/1.4887797] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ng SP, Koay EJ. Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. Ann Pancreat Cancer 2018;1:22. [PMID: 30198024 DOI: 10.21037/apc.2018.07.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Vogel J, Berman AT, Lin L, Pechet TT, Levin WP, Gabriel P, Khella SL, Singhal S, Kucharczuk JK, Simone CB 2nd. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment. Radiother Oncol. 2016;118:504-509. [PMID: 26895711 DOI: 10.1016/j.radonc.2016.02.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
3 Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K, Nonaka T, Ishikawa H, Okumura T, Sakurai H. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol 2019;136:37-43. [PMID: 31015127 DOI: 10.1016/j.radonc.2019.03.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
4 Ng SP, Herman JM. Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer. Cancers (Basel) 2018;10:E75. [PMID: 29547526 DOI: 10.3390/cancers10030075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
5 Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015;7:241-249. [PMID: 26483878 DOI: 10.4251/wjgo.v7.i10.241] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
6 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
7 Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:97-108. [PMID: 31225409 DOI: 10.14701/ahbps.2019.23.2.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol 2020;11:166-75. [PMID: 32175120 DOI: 10.21037/jgo.2019.03.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Houweling AC, Crama K, Visser J, Fukata K, Rasch CR, Ohno T, Bel A, van der Horst A. Comparing the dosimetric impact of interfractional anatomical changes in photon, proton and carbon ion radiotherapy for pancreatic cancer patients. Phys Med Biol 2017;62:3051-64. [PMID: 28252445 DOI: 10.1088/1361-6560/aa6419] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Jethwa KR, Tryggestad EJ, Whitaker TJ, Giffey BT, Kazemba BD, Neben-Wittich MA, Merrell KW, Haddock MG, Hallemeier CL. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol 2018;3:314-21. [PMID: 30202800 DOI: 10.1016/j.adro.2018.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
12 Boimel PJ, Berman AT, Li J, Apisarnthanarax S, Both S, Lelionis K, Larson GL, Teitelbaum U, Lukens JN, Ben-Josef E, Metz JM, Plastaras JP. Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:665-74. [PMID: 28890817 DOI: 10.21037/jgo.2017.03.04] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
13 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
14 Plastaras JP, Dionisi F, Wo JY. Gastrointestinal cancer: nonliver proton therapy for gastrointestinal cancers. Cancer J 2014;20:378-86. [PMID: 25415682 DOI: 10.1097/PPO.0000000000000085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Radiat Oncol 2019;14:71. [PMID: 31036034 DOI: 10.1186/s13014-019-1275-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
16 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
17 Verma V, Lazenby AJ, Zheng D, Bhirud AR, Ly QP, Are C, Sasson AR, Lin C. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol 2017;122:464-9. [PMID: 28089484 DOI: 10.1016/j.radonc.2016.12.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
18 Doyen J, Falk AT, Floquet V, Hérault J, Hannoun-Lévi JM. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev 2016;43:104-12. [PMID: 26827698 DOI: 10.1016/j.ctrv.2015.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
19 Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, Plastaras JP, Metz JM, Both S, Apisarnthanarax S. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. Pract Radiat Oncol. 2015;5:209-218. [PMID: 25703530 DOI: 10.1016/j.prro.2015.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
20 Chuong M, Badiyan SN, Yam M, Li Z, Langen K, Regine W, Morris C, Snider J 3rd, Mehta M, Huh S, Rutenberg M, Nichols RC. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. J Gastrointest Oncol 2018;9:687-93. [PMID: 30151265 DOI: 10.21037/jgo.2018.03.14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
21 Sio TT, Merrell KW, Beltran CJ, Ashman JB, Hoeft KA, Miller RC, Whitaker TJ, Wurgler SK, Tryggestad EJ. Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study. Physica Medica 2016;32:331-42. [DOI: 10.1016/j.ejmp.2015.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]